It is, thus, reasonable to think that NR4A modulation could be envisaged in view of restoring MZp Breg capacities, possibly in conjunction with therapies reducing excessive BAFF levels, already FDA-approved in the treatment of SLE. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.